CompletedNCT00190931
Atomoxetine compared with placebo for work productivity in adults with ADHD
About this title
Read the official source — NCT00190931Medication studyAges 18–49United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 49 years.
- Listed locations
- ColumbiaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 49 Years
- Official registry ID
- NCT00190931
- Official title
Show the full official title
A Double-Blind Study of Functional Outcomes With Atomoxetine-Hydrochloride and Placebo in Adult Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Columbia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride and placebo.
Who was this study for?
Listed age limits: 18 years to 49 years.
